HRP20160235T1 - Pripravak koji sadrži antibiotik i disperzant - Google Patents

Pripravak koji sadrži antibiotik i disperzant Download PDF

Info

Publication number
HRP20160235T1
HRP20160235T1 HRP20160235TT HRP20160235T HRP20160235T1 HR P20160235 T1 HRP20160235 T1 HR P20160235T1 HR P20160235T T HRP20160235T T HR P20160235TT HR P20160235 T HRP20160235 T HR P20160235T HR P20160235 T1 HRP20160235 T1 HR P20160235T1
Authority
HR
Croatia
Prior art keywords
product
infections
spp
infection
use according
Prior art date
Application number
HRP20160235TT
Other languages
English (en)
Croatian (hr)
Inventor
Deborah O'neil
Cedric Charrier
Original Assignee
Novabiotics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Limited filed Critical Novabiotics Limited
Publication of HRP20160235T1 publication Critical patent/HRP20160235T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
HRP20160235TT 2010-12-14 2011-12-14 Pripravak koji sadrži antibiotik i disperzant HRP20160235T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42300010P 2010-12-14 2010-12-14
GBGB1021186.0A GB201021186D0 (en) 2010-12-14 2010-12-14 Composition
PCT/GB2011/001721 WO2012080700A1 (en) 2010-12-14 2011-12-14 A composition comprising an antibiotic and a dispersant or an anti -adhesive agent
EP11808253.6A EP2651419B1 (en) 2010-12-14 2011-12-14 A composition comprising an antibiotic and a dispersant

Publications (1)

Publication Number Publication Date
HRP20160235T1 true HRP20160235T1 (hr) 2016-05-20

Family

ID=43567164

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160235TT HRP20160235T1 (hr) 2010-12-14 2011-12-14 Pripravak koji sadrži antibiotik i disperzant
HRP20210280TT HRP20210280T1 (hr) 2010-12-14 2021-02-18 Pripravak koji sadrži nepeptidni antibiotik i cisteamin

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210280TT HRP20210280T1 (hr) 2010-12-14 2021-02-18 Pripravak koji sadrži nepeptidni antibiotik i cisteamin

Country Status (27)

Country Link
US (3) US9782423B2 (enExample)
EP (2) EP3040076B1 (enExample)
JP (2) JP5964854B2 (enExample)
KR (1) KR101955636B1 (enExample)
CN (1) CN103732232B (enExample)
AU (3) AU2011343012C1 (enExample)
BR (2) BR122019015601B1 (enExample)
CA (1) CA2821032C (enExample)
CY (2) CY1117447T1 (enExample)
DK (2) DK2651419T3 (enExample)
ES (2) ES2565564T3 (enExample)
GB (1) GB201021186D0 (enExample)
HR (2) HRP20160235T1 (enExample)
HU (2) HUE027207T2 (enExample)
IL (2) IL276342B2 (enExample)
LT (1) LT3040076T (enExample)
MX (2) MX346664B (enExample)
NZ (1) NZ613076A (enExample)
PL (2) PL3040076T3 (enExample)
PT (1) PT3040076T (enExample)
RS (2) RS54815B1 (enExample)
RU (2) RU2739249C2 (enExample)
SG (3) SG191146A1 (enExample)
SI (2) SI3040076T1 (enExample)
SM (2) SMT201600121B (enExample)
UA (2) UA124661C2 (enExample)
WO (1) WO2012080700A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143889A1 (en) 2007-05-14 2008-11-27 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
US20150273025A1 (en) * 2012-09-28 2015-10-01 The Regents Of The University Of Michigan Apyrase treatments
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US12037497B2 (en) 2016-01-28 2024-07-16 Kimberly-Clark Worldwide, Inc. Anti-adherent composition against DNA viruses and method of inhibiting the adherence of DNA viruses to a surface
WO2017204806A1 (en) 2016-05-26 2017-11-30 Kimberly-Clark Worldwide, Inc. Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
EP3554491B1 (en) * 2016-12-15 2023-02-15 Zambon S.p.A. N-acetylcysteine for use as antibacterial agent
EP3366284A1 (en) 2017-02-27 2018-08-29 Zambon S.p.A. Association of n-acetylcysteine and colistin for use in bacterial infections
WO2018189687A1 (en) * 2017-04-10 2018-10-18 The University Of North Carolina At Chapel Hill Compounds, compositions and methods for inhibiting a pathogen and/or modifying mucus
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
FI3866775T3 (fi) * 2018-10-17 2025-07-10 Novabiotics Ltd Kysteamiini käytettäväksi keuhkosairauksien hoidossa
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN111053696B (zh) * 2019-11-19 2022-11-04 温州医科大学附属口腔医院 一种抑制细菌粘附的超疏水凝胶纳米涂层及制备方法
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (it) 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IT1178869B (it) 1984-03-07 1987-09-16 Cagliero Germano Prodotto per prevenire e combattere le tossicosi alimentari dovute a micotossine
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
CA2145093C (en) 1992-09-25 2007-04-10 Lawrence Leroy Kunz Therapeutic inhibitor of vascular smooth muscle cells
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
JP3749279B2 (ja) 1995-03-01 2006-02-22 日産化学工業株式会社 爪用抗真菌剤
US5624704A (en) * 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6086921A (en) 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000033895A1 (en) 1998-12-07 2000-06-15 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
ITMI20021881A1 (it) 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
ATE515261T1 (de) 2003-12-19 2011-07-15 Omega Bio Pharma Ip3 Ltd Zusammensetzungen zur behandlung von diabetes
EP1778720B1 (en) 2004-08-18 2010-09-01 Novabiotics Limited Antimicrobial peptides comprising an arginine- and/or lysine-containing motif
US20070093894A1 (en) * 2005-10-25 2007-04-26 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
ZA200805191B (en) 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
DE102006010642A1 (de) 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
US20080035141A1 (en) * 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
US20100209411A1 (en) * 2006-12-01 2010-08-19 Laclede, Inc. Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears
US20080131500A1 (en) * 2006-12-04 2008-06-05 The Board Of Regents Of The University Of Texas System Methods and compositions for rapid inactivation of proteins
WO2008092262A1 (en) 2007-01-31 2008-08-07 The Royal Institution For The Advancement Of Learning/Mcgill University Methods and compounds for treatment, prevention and diagnosis of parasitic infection and disease
GB0702021D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
WO2008124706A2 (en) 2007-04-06 2008-10-16 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Devices and methods for target molecule characterization
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
RU2371447C2 (ru) * 2007-10-05 2009-10-27 Общество С Ограниченной Ответственностью "Саентифик Фьючер Менеджмент" Конъюгат антибиотика и антибактериальное лекарственное средство на его основе
WO2009076722A1 (en) 2007-12-19 2009-06-25 The University Of Melbourne Method of protecting a surface from biological fouling
KR20100103565A (ko) * 2008-01-10 2010-09-27 에보니크 룀 게엠베하 촉진되고 조절된 활성 물질 방출을 갖는 코팅된 제약학적 또는 건강기능성 제제
CN102006785A (zh) 2008-02-17 2011-04-06 华扩达动物科学(I.P.3)有限公司 改善虾健康的材料和方法
CN102341105B (zh) * 2009-02-03 2014-09-17 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
US8815942B2 (en) * 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US20150071904A1 (en) 2012-01-06 2015-03-12 Trustees Of Boston University Compositions and methods to boost endogenous ros production from bacteria
US20160106689A1 (en) 2014-09-22 2016-04-21 Novabiotics Limited Use

Also Published As

Publication number Publication date
AU2018282257A1 (en) 2019-01-17
EP2651419B1 (en) 2016-02-10
CA2821032A1 (en) 2012-06-21
AU2011343012A1 (en) 2013-08-01
PL3040076T3 (pl) 2021-06-14
JP6483058B2 (ja) 2019-03-13
CN103732232A (zh) 2014-04-16
SI3040076T1 (sl) 2021-04-30
SI2651419T1 (sl) 2016-06-30
ES2856831T3 (es) 2021-09-28
US20140357592A1 (en) 2014-12-04
WO2012080700A1 (en) 2012-06-21
IL226879B (en) 2020-08-31
RU2013131391A (ru) 2015-01-20
DK2651419T3 (en) 2016-03-21
CY1123951T1 (el) 2022-05-27
MX2013006873A (es) 2013-07-05
KR20140029372A (ko) 2014-03-10
NZ613076A (en) 2014-12-24
RS54815B1 (sr) 2016-10-31
RU2016151115A3 (enExample) 2020-06-18
AU2011343012B2 (en) 2017-02-02
JP5964854B2 (ja) 2016-08-03
RS61469B1 (sr) 2021-03-31
AU2017201670A1 (en) 2017-03-30
CY1117447T1 (el) 2017-04-26
DK3040076T3 (da) 2021-02-22
HK1220911A1 (en) 2017-05-19
EP3040076B1 (en) 2020-12-09
GB201021186D0 (en) 2011-01-26
SG10201703290UA (en) 2017-06-29
RU2739249C2 (ru) 2020-12-22
JP2013545794A (ja) 2013-12-26
US11020414B2 (en) 2021-06-01
RU2607660C2 (ru) 2017-01-10
LT3040076T (lt) 2021-03-25
KR101955636B1 (ko) 2019-03-08
SMT201600121B (it) 2016-07-01
BR122019015601B1 (pt) 2021-02-02
PT3040076T (pt) 2021-02-25
PL2651419T3 (pl) 2016-08-31
UA124661C2 (uk) 2021-10-27
HUE027207T2 (en) 2016-10-28
HUE053813T2 (hu) 2021-07-28
SMT202100095T1 (it) 2021-03-15
US20120328671A1 (en) 2012-12-27
HK1185015A1 (zh) 2014-02-07
JP2016196495A (ja) 2016-11-24
US9782423B2 (en) 2017-10-10
AU2017201670B2 (en) 2018-12-20
BR112013015010B1 (pt) 2021-01-05
IL276342B2 (en) 2024-11-01
SG191146A1 (en) 2013-07-31
US9364491B2 (en) 2016-06-14
US20160158169A1 (en) 2016-06-09
EP3040076A1 (en) 2016-07-06
RU2016151115A (ru) 2018-11-14
UA114470C2 (uk) 2017-06-26
EP2651419A1 (en) 2013-10-23
CA2821032C (en) 2022-04-12
MX376284B (es) 2025-03-07
MX346664B (es) 2017-03-27
CN103732232B (zh) 2016-11-09
BR112013015010A2 (pt) 2016-08-09
HRP20210280T1 (hr) 2021-04-02
ES2565564T3 (es) 2016-04-05
IL276342B1 (en) 2024-07-01
IL276342A (en) 2020-09-30
AU2011343012C1 (en) 2017-04-20
SG10201510095YA (en) 2016-01-28

Similar Documents

Publication Publication Date Title
HRP20160235T1 (hr) Pripravak koji sadrži antibiotik i disperzant
El-Feky et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces
RU2011143399A (ru) Ингибирование организмов биопленки
Dinicola et al. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review.
Deysine Pathophysiology, prevention, and management of prosthetic infections in hernia surgery
JP2012522037A5 (enExample)
ES2750553T3 (es) Prevención y tratamiento de las infecciones microbianas
Marcinkiewicz et al. Antibiotic resistance: a" dark side" of biofilm‑associated chronic infections
ES2729968T3 (es) Composiciones antimicrobianas que comprenden nitratos de glicerilo
Holinka et al. Effects of selenium coating of orthopaedic implant surfaces on bacterial adherence and osteoblastic cell growth
Meije et al. Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection
Schwechter et al. Optimal irrigation and debridement of infected joint implants: an in vitro methicillin-resistant Staphylococcus aureus biofilm model
JP2017503852A (ja) 感染を制御するための材料および方法
JP2018500387A5 (enExample)
US20220175673A1 (en) Surgical device
JP2013508269A5 (enExample)
CN102753142A (zh) 含益生菌、抗生素和不饱和非酯化脂肪酸的直肠、阴道或尿道给药的栓剂
JP2015512386A5 (enExample)
JP7778671B2 (ja) バイオフィルム形成を阻害するためのリポソーム
RU2019105733A (ru) Молочнокислые бактерии и их применение для обработки с целью профилактики, ингибирования и/или уменьшения образования бактериальных биопленок
Fujimura et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
JP2024009968A5 (enExample)
CA3237640A1 (en) Methods for biofilm disruption
Oh et al. The effect of curcumin against in vitro adhesion of implant device-associated bacteria on nanosized titanium dioxide